Clinical Presentation of Chronic Myeloid Leukaemia and Its Correlation with Haematological Parameters in Kenya
DOI:
https://doi.org/10.62382/jcbt.v2i3.68Keywords:
Chronic myeloid leukaemia, Presenting symptoms, Clinical findings, BCR:ABL1, Blood counts, Bone marrow blastsAbstract
Background: Chronic myeloid leukaemia (CML) is commonly asymptomatic and is discovered incidentally in up to about 50% of patients in chronic phase, due to abnormally high white blood cell (WBC) counts. Commonest symptoms include fatigue and abdominal pain/discomfort, while some patients present with bleeding tendencies. Unusual manifestations include hearing and visual loss.
Methods: This was a retrospective analysis of data from patients attending the Glivec International Patient Assistance Clinic at the Nairobi Hospital between January 2006 and December 2018. In-formation sourced included demographic profiles, findings on physical examination, and laboratory values. Absolute, range, median and mean counts for white blood cells (WBC ×109/l), ab-solute neutrophil count (ANC×109/l), platelets (PLT ×109/l), haemoglobin (hgb, g/dl), BCR:ABL1 baseline levels, and bone marrow blast percentage at diagnosis. All parameters were tested against each of the clinical presentations.
Results: We enrolled 583 patients; the mean age was 39.8 years. The commonest symptom was abdominal swelling in 235 cases (40.3%); 70 (12%) experienced abdominal pain. Priapism occurred in 4 males (0.69%), blindness and deafness in 8 patients (1.37%). Splenomegaly was significantly more common among males than females (P = 0.015). Patients aged ≤ 20 years were more likely to be in heart failure (P = 0.032); leg swelling was more in those with high platelet counts (p=0.023). Unclear presentations were more common in those with high WBC counts (p=0.015). Total WBC counts and BCR:ABL1 levels were higher among younger patients (p=0.036, and 0.025, respectively). Patients with leg swelling had lower BCR:ABL1 levels (p=0.005), those in heart failure had significantly higher BCR:ABL1 levels at baseline compared with the rest (p=0.037). Patients with lymphadenopathy were more likely to have lower ANCs (p=0.035). Patients who had pallor had a significantly lower BCR:ABL1 values compared with those without (P = 0.025). Similarly, patients who had leg swelling had a significantly lower mean BCR:ABL1 percentage compared with those without (P = 0.005). In contrast, those in heart failure had significantly higher mean BCR:ABL1 values (P = 0.037). Those with lymphadenopathy had significantly lower absolute neutrophil counts compared with those without (P =0.035).
Conclusions: Clinical manifestations of CML cannot be explained merely by haematologic values. Complex biologic and physico-chemical factors should be further interrogated.
Downloads
References
Wang Y, Liang ZJ, Gale RP, Liao HZ, Ma J, et al. Chronic myeloid leukaemia: Biology and therapy. Blood Reviews. 2024, 65, 101196. DOI: 10.1016/j.blre.2024.101196
Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. British Journal of Haematology. 1997, 96(1), 111-116. DOI: 10.1046/j.1365-2141.1997.d01-1982.x
Schemionek M, Elling C, Kamp L, Spieker T, Berdel WE, et al. Role of spleen in chronic myelogenous leukaemia: Lessons from an inducible mouse model. Blood. 2010, 116(21), 3384. DOI: 10.1182/blood.V116.21.3384.3384
Litchman MA. Rheology of leukocytes, leukocyte suspensions, and blood in leukaemia: possible relationship to clinical manifestations. Journal of Clinical Investigations. 1973, 52(2), 350-358. DOI: 10.1172/JCI107191
Szeto SK, Mohamed S, Tsang CW, Chan CK. Massive retinal infiltrates as the presenting sign of chronic myeloid leukemia: Clinical and imaging features of leukemic retinopathy. European Journal of Ophthalmology. 2023, 33(1), NP55-NP63. DOI: 10.1177/11206721211048792
Holt JM, Gordon-Smith EC. Retinal abnormalities in diseases of the blood. The British Journal of Ophthalmology. 1969, 53(3), 145-160. DOI: 10.1136/bjo.53.3.145
Othieno-Abinya NA, Mwanda OW, Maina MD, Odhiambo AO, Mwanzi SA, et al. Haematological parameters in chronic myeloid leukaemia as determinants of clinical manifestations in this disease. Journal of Clinical Oncology. 2016, 34(15 suppl), e18529. DOI: 10.1200/JCO.2016.34.15_suppl.e18529
Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of ABL1 and BCR genes in chronic myelogenous leukaemia. Nature. 1985, 315(6020), 550-554. DOI: 10.1038/315550a0
Deininger MW, Goldman JM, Melo JV. The biology of chronic myeloid leukaemia. Blood. 2000, 96, 3343-56.
Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973, 243(5405), 290-293. DOI: 10.1038/243290a0
Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, Lee MS, O'Brien S, et al. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia. Clinical, Laboratory and prognostic correlations. Cancer. 1995, 76(6), 992-997. DOI: 10.1002/1097-0142(19950915)76:6<992::aid-cncr2820760612>3.0.co;2-l
Quintas-Cardama A, Cortes J. Molecular biology of BCR:ABL1-positive chronic myeloid leukaemia. Blood. 2009, 113(8), 1619-1630. DOI: 10.1182/blood-2008-03-144790
Chereda B, Melo JV. Natural course and biology of CML. Annals of Hematology. 2015, 94(Suppl 2), 107-121. DOI: 10.1007/s00277-015-2325-z
Balatzenko G, Vunditini BR, Margarita G. Correlation between BCR:ABL1 transcripts and blood cell counts in chronic myeloid leukaemia- a possible influence of mdr1 gene expression. Hematology Reports. 2011, 3(1), e3. DOI: 10.4081/hr.2011.e3
Liu ZH, Li SY, Bai O. Swollen lymph nodes may not be clinical manifestations of chronic myelogenous leukaemia: a case report and revision of literature. Therapeutics and Clinical Risk Management. 2017, 13, 1159-1162. DOI: 10.2147/TCRM.S147056
Inverardi D, Lazzarino M, Morra E, Bernasconi P, Merante S, et al. Extramedullary disease in Ph’-positive chronic myelogenous leukaemia: frequency, clinical features, and prognostic significance. Haematologica. 1990, 75(2), 146-148. PMID: 2358205
Woodson DL, Bennett DE, Sears DA. Extramedullary blastic transformation of chronic myelocytic leukaemia. Archives of Internal Medicine. 1974, 134(3), 523-526. DOI: 10.1001/archinte.1974.00320210133020
Balatzenko G, Vunditini BR, and Margarita G. Correlation between the types of BCR:ABL1 transcripts and blood cell counts in chronic myeloid leukaemia - a possible influence of mdr1 gene expression. Hematol Rep 2011;3(1):1-4. DOI: 10.4081/hr.2011.e1.
Inokuchi K, Inoue T, Tojo A, Futaki M, Miyake K, et al. A possible correlation between the type of BCR:ABL1 hybrid messenger RNA and platelet count in Philadelphia-positive chronic myeloid leukaemia. Blood. 1991, 78(12), 3125-3127. PMID: 1742479
Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, et al. The possible influences of B2A2 and B3A2 BCR:ABL1 protein structure on thrombopoiesis in chronic myeloid leukaemia. European Journal of Cancer. 2000, 36(11), 1395-1401. DOI: 10.1016/s0959-8049(00)00128-3
Piccin A, Fleming P, Eakins E, McGovern E, Smith OP, et al. Sickle cell disease and dental treatment. Journal of the Irish Dental Association. 2008, 54(2), 75-79. PMID: 18578383
Zureigat H, Mohamed AN, Alchirazi MA, Foster P, Elghoul Y, Dhakal A, et al. Cardiovascular profile of tyrosine kinase inhibitors in chronic myeloid leukemia: A 16-Year observational study. Blood. 2024, 144, (supplement 1). :DOI: 10.1182/blood-2024-222146
Berisha A, Placci A, Piccaluga PP. Cardiotoxicity of Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients. Hemato. 2023, 4(1), 68-75. DOI: 10.3390/hemato4010007
Gu A, Li JT, Li MY, Liu YB. Patient-derived xenograft model in cancer: establishment and applications. MedComm. 2025, 6(2), e70059. DOI: 10.1002/mco2.70059
Radich J, Yeung C, Wu D. New approaches to molecular monitoring in CML (and other diseases). Blood. 2019, 134(19), 1578-1584. DOI: 10.1182/blood.2019000838
Brandford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, et al. DesirABL1e performance characteristics for BCR:ABL1 measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008, 112(8), 3330-3338. DOI: 10.1182/blood-2008-04-150680
Riaz MA, Abubakar M, Ayyoub R, Khan AN, Hameed Y. Expression Analysis of Caspase-3 (CASP3) Gene in Leukemia Patients Using Quantitative Polymerase Chain Reaction (qPCR) and Western Blot Techniques. Journal of Cancer Biomoleculars and Therapeutics. 2024, 1(2), 10–16. DOI:10.62382/jcbt.v1i2.17
Archer KJ, Fu H, Mrózek K, Nicolet D, Mims AS, et al. Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia. The Innovation. 2024, 5(6), 100719. DOI: 10.1016/j.xinn.2024.100719
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Nicholas Anthony Othieno-Abinya, Joseph David M Maina, Angela Awino McLigeyo , Andrew Oluoch Odhiambo , Sitna Ali Mwanzi , Peter Omondi Oyiro, Matilda Ong’ondi, Shadrack Bonginkosi Shoba, Mohammed Ezzi, Robert Yatich Bett, Maureen Mukanga, Kevin Owuor, Pier Paolo Piccaluga
This work is licensed under a Creative Commons Attribution 4.0 International License.
